425380-38-7

Basic information

• Product Name: 4-bromo-7-chloro-1H-pyrrolo[2,3-c]pyridine
• Synonyms: 4-bromo-7-chloro-1H-pyrrolo[2,3-c]pyridine;1H-Pyrrolo[2,3-c]pyridine, 4-broMo-7-chloro-;4-BroMo-7-chloro-6-azaindole
• CAS NO: 425380-38-7
• Molecular Formula: C₇H₄BrClN₂
• Molecular Weight: 231
• EINECS: 200-589-5
• Mol File: 425380-38-7.mol
• Article Data: 12

Chemical Properties

• Melting Point: 230-231°
• Boiling Point: 367.8±37.0 °C(Predicted)
• Appearance: /
• Density: 1.878±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 12.15±0.40(Predicted)
• CAS DataBase Reference: 4-bromo-7-chloro-1H-pyrrolo[2,3-c]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-7-chloro-1H-pyrrolo[2,3-c]pyridine(425380-38-7)
• EPA Substance Registry System: 4-bromo-7-chloro-1H-pyrrolo[2,3-c]pyridine(425380-38-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 425380-38-7(Hazardous Substances Data)

Usage

General Description

4-Bromo-7-chloro-1H-pyrrolo[2,3-c]pyridine is a chemical compound with the molecular formula C7H4BrClN2. It is a heterocyclic compound that contains a pyrrole and pyridine ring fused together, with bromine and chlorine substituents at the 4 and 7 positions, respectively. 4-bromo-7-chloro-1H-pyrrolo[2,3-c]pyridine has potential applications in the pharmaceutical and agrochemical industries, as it can be used as a building block in the synthesis of various biologically active compounds. Additionally, 4-bromo-7-chloro-1H-pyrrolo[2,3-c]pyridine may also have uses in the field of materials science, although further research is needed to explore its potential in this area. Due to its unique structural features, this compound is of interest to researchers and chemists studying organic synthesis and drug discovery.

Upstream product

• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 
• 1826-67-1 vinyl magnesium bromide 

Downstream Products

• 446284-32-8 7-chloro-4-methoxy-1H-pyrrolo[2,3-c]pyridine 
• 701213-46-9 (R)-1-(4-benzoyl-3-methylpiperazin-1-yl)-2-(4-methoxy-7-(4-methyl-1H-1,2,3-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione 
• 701213-45-8 1-(4-benzoylpiperazin-1-yl)-2-(4-methoxy-7-(4-methyl-1H-1,2,3-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione 
• 701213-16-3 1-(4-benzoylpiperazin-1-yl)-2-(4-methoxy-7-(3-methoxy-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione 
• 701213-44-7 (R)-1-(4-benzoyl-3-methylpiperazin-1-yl)-2-(4-methoxy-7-(3-(methoxymethyl)-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione 
• 701213-43-6 1-(4-benzoylpiperazin-1-yl)-2-(4-methoxy-7-(3-(methoxymethyl)-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione 
• 701213-42-5 (R)-1-(4-benzoyl-3-methylpiperazin-1-yl)-2-(7-(3-ethyl-1H-1,2,4-triazol-1-yl)-4-methoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione 
• 701213-41-4 1-(4-benzoylpiperazin-1-yl)-2-(7-(3-ethyl-1H-1,2,4-triazol-1-yl)-4-methoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione 
• 701213-00-5 1-(3-(2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl)-4-methoxy-1H-pyrrolo[2,3-c]pyridin-7-yl)-N,N-dimethyl-1H-1,2,4-triazole-3-carboxamide 
• 701212-98-8 1-(3-(2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl)-4-methoxy-1H-pyrrolo[2,3-c]pyridin-7-yl)-N-ethyl-1H-1,2,4-triazole-3-carboxamide 
• 701212-99-9 1-(3-(2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl)-4-methoxy-1H-pyrrolo[2,3-c]pyridin-7-yl)-N-methyl-1H-1,2,4-triazole-3-carboxamide 
• 701213-01-6 1-(3-(2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl)-4-methoxy-1H-pyrrolo[2,3-c]pyridin-7-yl)-N-methyl-1H-pyrazole-3-carboxamide 
• 701213-60-7 1-(4-benzoylpiperazin-1-yl)-2-(7-(4-fluoro-1H-pyrazol-1-yl)-4-methoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione 
• 701212-64-8 (R)-1-(4-benzoyl-3-methylpiperazin-1-yl)-2-(7-(3-((dimethylamino)methyl)-1H-pyrazol-1-yl)-4-methoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione 

Relevant articles and documents

Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir

The optimization of the 4-methoxy-6-azaindole series of HIV-1 attachment inhibitors (AIs) that originated with 1 to deliver temsavir (3, BMS-626529) is described. The most beneficial increases in potency and pharmacokinetic (PK) properties were attained by incorporating N-linked, sp2-hybridized heteroaryl rings at the 7-position of the heterocyclic nucleus. Compounds that adhered to a coplanarity model afforded targeted antiviral potency, leading to the identification of 3 with characteristics that provided for targeted exposure and PK properties in three preclinical species. However, the physical properties of 3 limited plasma exposure at higher doses, both in preclinical studies and in clinical trials as the result of dissolution- and/or solubility-limited absorption, a deficiency addressed by the preparation of the phosphonooxymethyl prodrug 4 (BMS-663068, fostemsavir). An extended-release formulation of 4 is currently in phase III clinical trials where it has shown promise as part of a drug combination therapy in highly treatment-experienced HIV-1 infected patients.

METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Core chemotype diversification in the HIV-1 entry inhibitor class using field-based bioisosteric replacement

Demand remains for new inhibitors of HIV-1 replication and the inhibition of HIV-1 entry is an extremely attractive therapeutic approach. Using field-based bioisosteric replacements, we have further extended the chemotypes available for development in the HIV-1 entry inhibitor class. Moreover, using field-based disparity analysis of the compounds, 3D structure-activity relationships were derived that will be useful in the further development of these inhibitors towards clinical utility.